Table 3.
Association between previous aspirin use and prevalence of cancer subtype expressed as odds ratio for past cancer between previous regular aspirin use and not.
| Cancer type | Previous aspirin use | Adjusted Odds Ratioc (95%CI) | p-value | ||
|---|---|---|---|---|---|
| No | Yes | ||||
| (n = 16,944)a | (n = 2084)a | ||||
| Any cancer history | n | 3251 | 404 | 1.04 | 0.53 |
| % previous aspirin use | 19% | 19% | (0.92–1.17) | ||
| Bladder | n | 126 | 16 | 1.02 | 0.95 |
| % any cancer history | 4% | 4% | (0.59–1.77) | ||
| Blood (haematological), including Myeloma | n | 107 | 20 | 1.69 | 0.04 |
| % any cancer history | 3% | 5% | (1.02–2.81) | ||
| Breast | n | 713 | 122 | 1.34 | 0.008 |
| % any cancer history | 22% | 30% | (1.08–1.66) | ||
| Cervicalc (only females) | n | 68 | 10 | 1.2 | 0.61 |
| % any cancer history | 4% | 5% | (0.59–2.44) | ||
| Colon/Rectum | n | 430 | 42 | 0.93 | 0.67 |
| % any cancer history | 13% | 10% | (0.67–1.30) | ||
| Melanoma | n | 626 | 58 | 0.99 | 0.94 |
| % any cancer history | 19% | 14% | (0.75–1.31) | ||
| Ovarian/Endometriumc (only females) | n | 121 | 15 | 0.90 | 0.72 |
| % any cancer history | 7% | 7% | (0.51–1.59) | ||
| Prostatec (only males) | n | 818 | 107 | 0.96 | 0.70 |
| % any cancer history | 52% | 53% | (0.76–1.20) | ||
| All other cancersb | n | 532 | 49 | 0.71 | 0.03 |
| % any cancer history | 16% | 12% | (0.52–0.97) | ||
a
2 participants who did not provide details of past aspirin use were excluded from this table.
b
‘All other cancers’ includes gall bladder/bile duct, thyroid, brain, kidney, liver, lung, pancreatic, stomach/oesophagus and other.
c
Odds ratio presented for past cancer history between previous regular aspirin use and not, adjusted for age, sex and country, except for those cancers expressed relative to a single sex, as indicated (cervical, ovarian/endometrium, prostate).